TrialCancer medicine2021

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.

Pilar Garrido et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.